Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Dec 19, 2023 8:34pm
130 Views
Post# 35792910

RE:RE:RE:Exciting Developments Unveiled: A Deep Dive into Spectral's

RE:RE:RE:Exciting Developments Unveiled: A Deep Dive into Spectral's If nothing else, it speaks volumes about what our final demand might be once approved.  There's been some kerfuffle that our slow enrollment implies that our end demand/penetration will be low, but that couldn't be further from the truth.  We currently have a 100+ people per week desperately trying to get PMX.  And that's just from 20 hospitals.  When you extrapolate that demand to all the hospitals in the USA and you can easily see that PMX will definitely be in high demand.  I mean how many hospitals are there in the US, I know it's not just the 20 set up for the Tigris trial right.
<< Previous
Bullboard Posts
Next >>